ResearcherUniversidade do PortoActive in the last 2 years
Juliana Calheiros
Matched on ORCID iD 0000-0001-5895-6951; OpenAlex author ID A5053559023. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 5
2023: 2 papers · 2024: none · 2025: 1 paper
Papers 3
- A first-in-class inhibitor of homologous recombination DNA repair counteracts tumour growth, metastasis and therapeutic resistance in pancreatic cancer. Co-author DOI 10.1186/s13046-025-03389-5↗
- Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53. Co-author DOI 10.1016/j.bbcan.2023.188914↗
- Antitumor Activity of the Xanthonoside XGAc in Triple-Negative Breast, Ovarian and Pancreatic Cancer by Inhibiting DNA Repair. Co-author DOI 10.3390/cancers15245718↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Lucı́lia Saraiva · 3 shared papers, 2023–2025 · strength 0.70
- Paper Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53. DOI 10.1016/j.bbcan.2023.188914↗
- Paper A first-in-class inhibitor of homologous recombination DNA repair counteracts tumour growth, metastasis and therapeutic… DOI 10.1186/s13046-025-03389-5↗
- Paper Antitumor Activity of the Xanthonoside XGAc in Triple-Negative Breast, Ovarian and Pancreatic Cancer by Inhibiting DNA … DOI 10.3390/cancers15245718↗
- Vincenzo Corbo · 2 shared papers, 2023–2025 · strength 0.51
- Paper Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53. DOI 10.1016/j.bbcan.2023.188914↗
- Paper A first-in-class inhibitor of homologous recombination DNA repair counteracts tumour growth, metastasis and therapeutic… DOI 10.1186/s13046-025-03389-5↗
- Tao Wang · 1 shared paper, 2025 · strength 0.20
- Elena Fiorini · 1 shared paper, 2025 · strength 0.20
- Sónia A. Melo · 1 shared paper, 2025 · strength 0.20
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.